Amneal Pharmaceuticals, Inc. (AMRX)
17.78
-0.13
(-0.73%)
USD |
NASDAQ |
Aug 24, 16:00
17.77
-0.01
(-0.06%)
After-Hours: 20:00
Amneal Pharmaceuticals Enterprise Value : 8.459B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 8.459B |
| August 20, 2026 | 8.455B |
| August 19, 2026 | 8.523B |
| August 18, 2026 | 8.548B |
| August 17, 2026 | 8.621B |
| August 14, 2026 | 8.535B |
| August 13, 2026 | 8.254B |
| August 12, 2026 | 8.379B |
| August 11, 2026 | 8.200B |
| August 10, 2026 | 8.449B |
| August 07, 2026 | 8.532B |
| August 06, 2026 | 8.510B |
| August 05, 2026 | 8.634B |
| August 04, 2026 | 8.641B |
| August 03, 2026 | 8.759B |
| July 31, 2026 | 8.590B |
| July 30, 2026 | 8.647B |
| July 29, 2026 | 8.839B |
| July 28, 2026 | 8.730B |
| July 27, 2026 | 8.516B |
| July 24, 2026 | 8.462B |
| July 23, 2026 | 8.478B |
| July 22, 2026 | 8.408B |
| July 21, 2026 | 8.519B |
| July 20, 2026 | 8.328B |
| Date | Value |
|---|---|
| July 17, 2026 | 8.439B |
| July 16, 2026 | 8.500B |
| July 15, 2026 | 8.232B |
| July 14, 2026 | 8.069B |
| July 13, 2026 | 8.226B |
| July 10, 2026 | 8.171B |
| July 09, 2026 | 8.174B |
| July 08, 2026 | 8.155B |
| July 07, 2026 | 8.184B |
| July 06, 2026 | 8.143B |
| July 02, 2026 | 8.216B |
| July 01, 2026 | 8.158B |
| June 30, 2026 | 8.267B |
| June 29, 2026 | 8.095B |
| June 26, 2026 | 8.076B |
| June 25, 2026 | 8.105B |
| June 24, 2026 | 8.089B |
| June 23, 2026 | 7.895B |
| June 22, 2026 | 7.719B |
| June 18, 2026 | 7.751B |
| June 17, 2026 | 7.773B |
| June 16, 2026 | 7.764B |
| June 15, 2026 | 7.761B |
| June 12, 2026 | 7.748B |
| June 11, 2026 | 7.792B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Liquidia Corp. | 6.013B |
| Eli Lilly & Co. | 1.228T |
| Indivior Pharmaceuticals, Inc. | 4.638B |
| Viatris, Inc. | 31.07B |
| Pfizer Inc. | 211.77B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 69.61M |
| Revenue (Quarterly) | 796.20M |
| Total Expenses (Quarterly) | 738.54M |
| EPS Diluted (Quarterly) | 0.1757 |
| Gross Profit Margin (Quarterly) | 42.01% |
| Profit Margin (Quarterly) | 8.74% |
| Earnings Yield | 2.70% |
| Operating Earnings Yield | 8.19% |
| Normalized Earnings Yield | 3.494 |